WCLC 2025 - Posters & ePosters-P2.10.16 Paclitaxel Liposome Combined With Immunotherapy in the First-Line Treatment of Advanced NSCLC: Updated Results of a Real-World Study

P2.10.16 Paclitaxel Liposome Combined With Immunotherapy in the First-Line Treatment of Advanced NSCLC: Updated Results of a Real-World Study

Back to course

Pdf Summary

This real-world study evaluated the effectiveness and safety of combining paclitaxel liposome-based chemotherapy with immunotherapy as first-line treatment in 336 Chinese patients with advanced non-small cell lung cancer (NSCLC) across eight hospitals from April 2020 to January 2025. Paclitaxel liposome, a liposome-encapsulated formulation avoiding toxic solvents like polyethoxylated castor oil, lessens hypersensitivity reactions compared to conventional paclitaxel.<br /><br />Key patient characteristics included a median age of 68.5 years, predominantly male (95.2%), and mostly squamous cell carcinoma histology (71.4%). Most patients received carboplatin as the platinum agent and immunotherapy agents such as tislelizumab (57.1%).<br /><br />After a median follow-up of 14.9 months, results showed a median progression-free survival (PFS) of 13.07 months, with 1- and 2-year PFS rates of 53.1% and 28.6%, respectively. Overall survival (OS) rates at 1 and 2 years were 90.7% and 73.7%. The objective response rate (ORR) was 63.1%, with a disease control rate (DCR) of 94.6%. Multivariate analysis identified treatment cycles of paclitaxel liposome and achieving ORR as independent predictors of longer PFS. Age and smoking were also significant factors affecting PFS.<br /><br />Adverse events were common (94.6%) but manageable, with 63.4% grade 3 or higher. Most frequent adverse events involved bone marrow suppression, gastrointestinal symptoms, and liver function abnormalities, consistent with known drug profiles.<br /><br />The study concluded that paclitaxel liposome combined with immunotherapy is an effective, safe, and viable first-line treatment option in advanced NSCLC patients, showing robust efficacy without unexpected toxicity. No funding was received, and authors declared no conflicts of interest.

Asset Subtitle

Liyan Jiang

Meta Tag

Speaker Liyan Jiang

Topic Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

Keywords

paclitaxel liposome

immunotherapy

non-small cell lung cancer

NSCLC

first-line treatment

progression-free survival

overall survival

objective response rate

adverse events

Chinese patients